Clinical evidence demonstrates that treatment with immune checkpoint inhibitor
immunotherapy agents can have considerable benefit across multiple tumours. However …

DNA double-strand breaks foster tumorigenesis and cell death. Two distinct mechanisms
can be activated by the cell for DNA repair: the accurate mechanism of homologous …

Gastrointestinal stromal tumors (GIST) are characterized by a strong KIT receptor activation
most often resulting from KIT mutations. In a smaller subgroup of tumors without KIT …

In KIT/PDGFRA wild-type gastrointestinal stromal tumors (wt-GISTs), BRAF mutations are
regarded as alternative pathogenic events driving tumorigenesis. In our study, we aimed at …

Background The approval of vemurafenib in the US 2011 and in Europe 2012 improved the
therapy of not resectable or metastatic melanoma. Patients carrying a substitution of valine …

Gastrointestinal stromal tumors (GISTs) typically express high levels of the Kit‐receptor. The
majority of GISTs carry mutations in the c‐kit protooncogene clustering in exon 11. The …

Purpose: To identify novel mechanisms of resistance to third-generation EGFR inhibitors in
patients with lung adenocarcinoma that progressed under therapy with either AZD9291 or …

Gastrointestinal stromal tumors (GISTs) are mesenchymal neoplasms driven by oncogenic,
mutational activation of KIT or platelet-derived growth factor receptor α (PDGFRA). GIST …

Introduction Although KRAS mutations in NSCLC have been considered mutually exclusive
driver mutations for a long time, there is now growing evidence that KRAS-mutated NSCLC …

Gastrointestinal stromal tumors (GISTs) are often associated with activating KIT mutations,
affecting regulatory domains of the KIT tyrosine kinase. Sporadic mastocytosis in adults is …